Roche seeks FDA approval of RA drug Actemra

Roche has filed its cutting-edge rheumatoid arthritis drug Actemra for FDA approval. That's a key milestone for the antibody therapy, the first that promises to control the inflammatory response mechanism by inhibiting the interleukin-6 receptor. Most current therapies are anti-TNFs. Actemra was developed by Japan's Chugai, which is owned by Roche.

- check out the release for more info
- see the report from MarketWatch

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.